- Home
- HSCS vs XRTX Comparison
HSCS vs XRTX Comparison
Compare HSCS & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSCS
- XRTX
- Stock Information
- Founded
- HSCS 2007
- XRTX 2011
- Country
- HSCS United States
- XRTX Canada
- Employees
- HSCS N/A
- XRTX N/A
- Industry
- HSCS Medical Specialities
- XRTX Pharmaceuticals and Biotechnology
- Sector
- HSCS Health Care
- XRTX Health Care
- Exchange
- HSCS Nasdaq
- XRTX Nasdaq
- Market Cap
- HSCS 3.2M
- XRTX 3.0M
- IPO Year
- HSCS 2022
- XRTX N/A
- Fundamental
- Price
- HSCS $3.17
- XRTX $0.89
- Analyst Decision
- HSCS Strong Buy
- XRTX
- Analyst Count
- HSCS 2
- XRTX 0
- Target Price
- HSCS $13.50
- XRTX N/A
- AVG Volume (30 Days)
- HSCS 15.1K
- XRTX 272.2K
- Earning Date
- HSCS 03-13-2025
- XRTX 11-15-2024
- Dividend Yield
- HSCS N/A
- XRTX N/A
- EPS Growth
- HSCS N/A
- XRTX N/A
- EPS
- HSCS N/A
- XRTX N/A
- Revenue
- HSCS $14,700.00
- XRTX N/A
- Revenue This Year
- HSCS $174.19
- XRTX N/A
- Revenue Next Year
- HSCS $4,100.00
- XRTX N/A
- P/E Ratio
- HSCS N/A
- XRTX N/A
- Revenue Growth
- HSCS 151.28
- XRTX N/A
- 52 Week Low
- HSCS $2.36
- XRTX $0.85
- 52 Week High
- HSCS $18.50
- XRTX $7.00
- Technical
- Relative Strength Index (RSI)
- HSCS 39.08
- XRTX 33.98
- Support Level
- HSCS $3.11
- XRTX $0.88
- Resistance Level
- HSCS $3.45
- XRTX $0.97
- Average True Range (ATR)
- HSCS 0.17
- XRTX 0.06
- MACD
- HSCS -0.02
- XRTX -0.01
- Stochastic Oscillator
- HSCS 8.70
- XRTX 8.33
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.
About XRTX XORTX Therapeutics Inc.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.